676 related articles for article (PubMed ID: 30644983)
61. Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö
Mult Scler; 2018 May; 24(6):777-785. PubMed ID: 29685071
[TBL] [Abstract][Full Text] [Related]
62. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
[TBL] [Abstract][Full Text] [Related]
63. Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.
Beiki O; Frumento P; Bottai M; Manouchehrinia A; Hillert J
JAMA Neurol; 2019 Jun; 76(6):665-671. PubMed ID: 30882868
[TBL] [Abstract][Full Text] [Related]
64. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.
Le Page E; Leray E; Taurin G; Coustans M; Chaperon J; Morrissey SP; Edan G
J Neurol Neurosurg Psychiatry; 2008 Jan; 79(1):52-6. PubMed ID: 17846110
[TBL] [Abstract][Full Text] [Related]
65. Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis.
Comi G; Freedman MS; Meca-Lallana JE; Vermersch P; Kim BJ; Parajeles A; Edwards KR; Gold R; Korideck H; Chavin J; Poole EM; Coyle PK
BMC Neurol; 2020 Oct; 20(1):364. PubMed ID: 33023488
[TBL] [Abstract][Full Text] [Related]
66. Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western Austria.
Bsteh G; Algrang L; Hegen H; Auer M; Wurth S; Di Pauli F; Deisenhammer F; Berger T
Mult Scler; 2020 Jan; 26(1):69-78. PubMed ID: 30507345
[TBL] [Abstract][Full Text] [Related]
67. Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study.
Sorensen PS; Pontieri L; Joensen H; Heick A; Rasmussen PV; Schäfer J; Ratzer R; Pihl CE; Sellebjerg F; Magyari M
Mult Scler Relat Disord; 2023 Feb; 70():104491. PubMed ID: 36623393
[TBL] [Abstract][Full Text] [Related]
68. Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study.
Curro' D; Vuolo L; Gualandi F; Bacigalupo A; Roccatagliata L; Capello E; Uccelli A; Saccardi R; Sormani MP; Mancardi G
Mult Scler; 2015 Oct; 21(11):1423-30. PubMed ID: 25583838
[TBL] [Abstract][Full Text] [Related]
69. Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial.
Massacesi L; Tramacere I; Amoroso S; Battaglia MA; Benedetti MD; Filippini G; La Mantia L; Repice A; Solari A; Tedeschi G; Milanese C
PLoS One; 2014; 9(11):e113371. PubMed ID: 25402490
[TBL] [Abstract][Full Text] [Related]
70. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L
BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355
[TBL] [Abstract][Full Text] [Related]
71. Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: The CLARENCE study.
Brownlee W; Amin A; Ashton L; Herbert A
Mult Scler Relat Disord; 2023 Nov; 79():104951. PubMed ID: 37639781
[TBL] [Abstract][Full Text] [Related]
72. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
Hettle R; Harty G; Wong SL
J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
[TBL] [Abstract][Full Text] [Related]
73. Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy.
Chalmer TA; Kalincik T; Laursen B; Sorensen PS; Magyari M;
J Neurol; 2019 Feb; 266(2):306-315. PubMed ID: 30515628
[TBL] [Abstract][Full Text] [Related]
74. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
[TBL] [Abstract][Full Text] [Related]
75. Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity.
Juto A; Fink K; Al Nimer F; Piehl F
Mult Scler Relat Disord; 2020 Jan; 37():101468. PubMed ID: 31683231
[TBL] [Abstract][Full Text] [Related]
76. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
Nikfar S; Rahimi R; Abdollahi M
Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
[TBL] [Abstract][Full Text] [Related]
77. Impact of disease-modifying treatments in North African migrants with multiple sclerosis in France.
Lebrun C; Debouverie M; Jeannin S; Pittion-Vouyovitch S; Bayreuther C; Berthier F
Mult Scler; 2008 Aug; 14(7):933-9. PubMed ID: 18573824
[TBL] [Abstract][Full Text] [Related]
78. Effects of adjunct glucosamine sulfate on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized, placebo-controlled trial.
Shaygannejad V; Janghorbani M; Savoj MR; Ashtari F
Neurol Res; 2010 Nov; 32(9):981-5. PubMed ID: 20223094
[TBL] [Abstract][Full Text] [Related]
79. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF
Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960
[TBL] [Abstract][Full Text] [Related]
80. Untreated patients with multiple sclerosis: A study of French expert centers.
Moisset X; Fouchard AA; Pereira B; Taithe F; Mathey G; Edan G; Ciron J; Brochet B; De Sèze J; Papeix C; Vermersch P; Labauge P; Defer G; Lebrun-Frenay C; Moreau T; Laplaud D; Berger E; Pelletier J; Stankoff B; Gout O; Thouvenot E; Heinzlef O; Al-Khedr A; Bourre B; Casez O; Cabre P; Montcuquet A; Créange A; Camdessanché JP; Bakchine S; Maurousset A; Hankiewicz K; Pottier C; Maubeuge N; Dimitri Boulos D; Nifle C; Vukusic S; Clavelou P;
Eur J Neurol; 2021 Jun; 28(6):2026-2036. PubMed ID: 33650261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]